o a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number Filing Date		10790574		
		2004-03-01		
First Named Inventor	John	D. Mehr		
Art Unit		2153	Ī	
Examiner Name Unk		own		
Attorney Docket Number		MS307141.01/MSFTP573US	_	

				U.S.	PATENTS		Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Releva	Columns,Lines where nt Passages or Relevant Appear
	1	6161130		2000-12-12	Horvitz et al.		
	2	6842773		2005-01-11	Raiston et al.		
	3	6751348		2004-06-15	Buzuloiu et al		
	4	6768991		2004-07-24	Heamden		
If you wis	h to a	d additional U.S. Pater	t citatio	n information pl	lease click the Add button.		Add
			U.S.P	ATENT APPLI	CATION PUBLICATIONS		Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Releva	Columns,Lines where nt Passages or Relevant Appear
	1	20030041126	A1	2003-02-27	Buford et al.		
	2	20030016872	A1	2003-01-23	Sun		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10790574		
Filing Date		2004-03-01		
First Named Inventor	John	D. Mehr		
Art Unit		2153		
Examiner Name	Unkno	own		
Attorney Docket Number		MS307141.01/MSFTP573US		

	3	20040199585	A1	2084-16	1-07	Wang					
If you wish	If you wish to add additional U.S. Published Application citation information please click the Add button. Add										
	FOREIGN PATENT DOCUMENTS Remove										
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴		Name of Patentee Applicant of cited Document	or	Pages,Colur where Relev Passages or Figures App	/ant r Relevant	Ţ5
	1										
If you wish	to ac	d additional Foreign Pa	atent Do	cument	citation	information pl	ease click the Add	button	Add		
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove		
Examiner Initials*	Cite No							Ţ5			
	Federal Trade Commission: "False Claims in Span", A report by the FTC's division of marketing practices, April 30, 2003, http://www.ftc.gov/reports/spann/0304/25spannreport.pdf										
	2 HANSELL. Tindement is losing ground in battle against spam", The New York Times: Technology section, 22 April 2003.										
If you wish to add additional non-patent literature document citation information please click the Add button Add											
EXAMINER SIGNATURE											
Examiner Signature Date Considered											
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.											

See Kint Code of USPTO Petert Documents at twent_USETO_CODy or MPEP 901.04. * Enter dotte that issued the document, by the two-left or gold or Kint Code or USPTO Peter Document, the code common of the year of the region of the Emporer period process to be sent or the plasted document. * Kint of document by the opportunities symbols as indicated on the document under WIPO Standard ST.16 if possible. * Applicant is to place a check man's here if Emploits angular contractions attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number Filing Date First Named Inventor John			10790574		
			2004-03-01 D. Mehr		
		John			
	Art Unit		2153		
Examiner Name Unknown Attorney Docket Number		Unkno	own		
		er	MS307141.01/MSFTP573US		

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to make t	the appropriate selection(s):
---------------	----------	--------------------	-------------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.37(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any involved designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(s).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Himanshu S. Amin/	Date (YYYY-MM-DD)	2007-05-10
Name/Print	Himanshu S. Amin	Registration Number	40894

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Cfiling. U.S. Operatment of Commence, P. 0. Box 1450, Alexandrin, V.S. 2313-1450. D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandrin, V.S. 2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.